Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Inclusion criteria: * Patient hospitalized with a primary diagnosis of worsening heart failure ≥ 18 years of age, male or female. * Patients with a diagnosis of acute heart failure expressed by symptoms (dyspnea or fatigability - NYHA Class III-IV) and signs of fluid overload (i.e., jugular venous distension, edema or positive rales auscultation or pulmonary congestion on chest x-ray) at the time of hospitalization. * LVEF \< 40% (measured within the last 6 months). * Hospitalization for ADHF and remain "stabilized" for at least 6 hours (defined as SBP ≥ 110 mm Hg after acute decompensated episode) and did not receive IV vasodilators (other than nitrates) and/or IV inotropic drugs at anytime from ADHF presentation to time of randomization. * Elevated BNP at Visit 1 or at randomization (BNP ≥ 400 pg/ml). * Patients with a history of chronic heart failure on standard therapy defined as requiring HF treatment for at least 30 days before the current hospitalization (NYHA Class II - IV). Exclusion Criteria: * Patients that required any use of IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for worsening HF to randomization. * Concomitant use of ACEI and ARB at randomization. * Right heart failure due to pulmonary disease. * Diagnosis of postpartum cardiomyopathy. * Myocardial infarction or cardiac surgery, including percutaneous transluminal coronary angioplasty (PTCA), within past 3 months. * Patients with a history of heart transplant or who are on a transplant list. * Unstable angina or coronary artery disease likely to require coronary artery bypass graft (CABG) or PTCA before randomization. Other protocol-defined inclusion/exclusion criteria applied.